NEW YORK (GenomeWeb News) — Novartis has licensed Caliper Life Sciences’ intellectual property covering non-invasive optical imaging methods, Caliper said today.
Under the multi-year agreement, the drug maker will use Caliper’s Optical Imaging patent suite, which includes imaging systems, reagents, related applications, and methods and services, Caliper said.
According to Caliper, non-invasive optical imaging enables scientists to visualize, track, and quantify biological processes at the molecular level in vivo with high throughput and “relatively low cost.”
Caliper acquired its in vivo imaging technology through last year’s $80 million acquisition of Xenogen, at which point the company changed its name to Caliper Life Sciences.
Financial terms of the license were not released.